---
title: "Novogene released its 2024 annual performance, with a net profit attributable to the parent company of 197 million yuan, a year-on-year increase of 10.52%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/235864703.md"
description: "According to the Zhitong Finance APP, Novogene disclosed its 2024 annual report, stating that the company achieved revenue of 2.111 billion yuan during the reporting period, a year-on-year increase of 5.45%; net profit attributable to shareholders was 197 million yuan, a year-on-year increase of 10.52%; net profit excluding non-recurring items was 171 million yuan, a year-on-year increase of 21.98%; basic earnings per share were 0.48 yuan. The company plans to distribute a cash dividend of 0.05 yuan per share (tax included) to all shareholders"
datetime: "2025-04-14T11:57:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/235864703.md)
  - [en](https://longbridge.com/en/news/235864703.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/235864703.md)
generator: "portal-rs"
---

# Novogene released its 2024 annual performance, with a net profit attributable to the parent company of 197 million yuan, a year-on-year increase of 10.52%

According to the Zhitong Finance APP, Novogene (688315.SH) disclosed its annual report for 2024. During the reporting period, the company achieved revenue of 2.111 billion yuan, a year-on-year increase of 5.45%; net profit attributable to shareholders was 197 million yuan, a year-on-year increase of 10.52%; net profit excluding non-recurring gains and losses was 171 million yuan, a year-on-year increase of 21.98%; basic earnings per share were 0.48 yuan. The company plans to distribute a cash dividend of 0.05 yuan per share (including tax) to all shareholders

### Related Stocks

- [688315.CN](https://longbridge.com/en/quote/688315.CN.md)

## Related News & Research

- [Sword Group announces H1 2026 liquidity agreement report for Jan. 1–Jun. 30](https://longbridge.com/en/news/297356750.md)
- [XINT: Q2 2026 saw higher sales, clinical progress for XSTEM, and strengthened financing](https://longbridge.com/en/news/297290880.md)
- [Endovia Health opens FDA INAD file for CannEpil veterinary program](https://longbridge.com/en/news/296915045.md)
- [Paramount Resources Ltd. (OTCMKTS:PRMRF) Receives Consensus Recommendation of "Moderate Buy" from Brokerages](https://longbridge.com/en/news/297146200.md)
- [Revelop buys Malmen 12 community property in central Malmo](https://longbridge.com/en/news/297157133.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**